Royalty Pharma plc（RPRX）宣布以2.4亿美元现金及潜在里程碑付款的对价，收购罗氏（Roche）旗下脊髓性肌萎缩症治疗药物Evrysdi（利司扑兰）的剩余特许权权益。此次交易将强化Royalty Pharma在对该款高需求药物收益流的控制权，进一步扩大其罕见病治疗领域的资产组合。
根据协议条款，除前期付款外，未来可能基于Evrysdi的销售表现触发额外里程碑款项。Evrysdi作为口服疗法，自上市以来因其便捷性及疗效受到市场广泛认可，已成为脊髓性肌萎缩症领域的重要治疗选项。
Royalty Pharma长期专注于收购生物医药产品的特许权收益，此次收购延续了其通过战略投资获取长期稳定现金流的商业模式。该交易预计将为公司带来可持续的收入增长，并增强其在全球特许权投资领域的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.